2025-10-30 - Analysis Report
Okay, here's a report summarizing the analysis of Tempus AI Inc. (TEM), incorporating the provided data and news headlines.

## Tempus AI (TEM) Stock Analysis

**Company Overview:** Tempus AI Inc. is a technology company focused on precision medicine through AI-driven diagnostics and data analysis.

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 44.52%
*   **VOO Cumulative Return:** 33.27%
*   **Absolute Outperformance:** TEM outperformed VOO by 11.25%
*   **Dispersion:** (Max: 74.4, Min: -40.6, Current: 16.3)
*   **Relative Dispersion:** 49.5

**Analysis:** TEM has outperformed the S&P 500 (VOO) significantly. The relative dispersion of 49.5 suggests that TEM's current outperformance is near the median of its historical range relative to VOO. It's important to note that relative dispersion indicates where the current outperformance sits within the historical range of outperformance, not necessarily that it is performing better than 50% of similar stocks.

**Alpha, Beta Analysis:**

| Year      | CAGR   | MDD   | Alpha  | Beta | Cap (B) |
| :---------- | :----- | :----- | :----- | :--- | :------ |
| 2023-2025 | 45.0% | 77.0% | 12.0% | 0.3  | 15.5   |

*   **CAGR (Compound Annual Growth Rate):**  45.0% is a strong growth rate.
*   **MDD (Maximum Drawdown):** 77.0% is a very high drawdown, indicating substantial risk and volatility.
*   **Alpha:** 12.0% suggests TEM generates returns above what would be expected based on market movements.
*   **Beta:** 0.3 indicates that TEM is significantly less volatile than the market, and tends to increase 30% for every 100% increase in the market.
*   **Cap (B):** 15.5B market cap.

**Analysis:** The high CAGR and positive alpha are encouraging. However, the very high MDD (77.0%) indicates that the stock can experience significant declines.  The Beta of 0.3 suggests less volatility compared to the overall market.

### 2. Recent Price Action

*   **Current Price:** $88.76
*   **Last Market Price:** $89.00 (Previous Close: $86.59, Change: 2.78)
*   **5-Day Moving Average:** $88.38
*   **20-Day Moving Average:** $91.56
*   **60-Day Moving Average:** $81.43

**Analysis:** The current price is below the 20-day moving average but above the 5-day and 60-day moving averages. The price increase of $2.78 from the previous close shows positive short-term momentum.

### 3. Technical Indicators & Market Risk

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 32.12 (Approaching Oversold)
*   **PPO (Percentage Price Oscillator):** -1.01 (Bearish)
*   **Hybrid Signal:**  Cash_79%_Sell (Sell 79.9% of holdings - Risky - MRI:0.50)
*   **Recent (20-day) Relative Dispersion Change:** -1.7 (Short-term decline)
*   **Expected Return (%):** NaN (No Data)

**Analysis:** The MRI indicates a high investment recommendation. However, the RSI suggests the stock is approaching oversold territory, potentially indicating a buying opportunity. The negative PPO points to bearish momentum. The hybrid signal advocating to sell 79.9% of holdings due to risk indicates caution. The decrease in relative dispersion suggests a recent underperformance compared to VOO.

### 4. Recent News & Significant Events

*   **Positive Catalysts:**
    *   Analyst price target of $110 based on AI adoption in medicine.
    *   Data partnership with Whitehawk Therapeutics.
    *   Participation in the Stifel 2025 Healthcare Conference.
    *   Multiple FDA approvals enhancing AI-driven diagnostics.
*   **Negative Catalysts:**
    *   TD Cowen downgrading the stock due to valuation catching up with growth.

**Analysis:** Recent news presents a mixed picture. Positive developments like analyst upgrades, partnerships, conference participation, and FDA approvals are counterbalanced by a downgrade due to valuation concerns.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~2.21)
*   **Opinions:** 12
*   **Target Price:** Avg: $82.50 / High: $110.00 / Low: $60.00

**Analysis:** Analyst consensus is "Buy" with an average price target of $82.50.  However, the high price target of $110 suggests potential upside, while the low of $60 indicates downside risk.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 예상 EPS |
| :----------- | :------ | :------- |
| 2025-08-08 | -0.22 | -0.2299 |
| 2025-05-06 | -0.24 | -0.2600 |
| 2025-02-24 | -0.18 | -0.1500 |
| 2024-11-04 | -0.25 | -0.2661 |
| 2024-08-06 | -0.63 | -0.5900 |

**Analysis:** TEM has consistently reported negative EPS. However, in most recent quarters, the EPS has either beaten expectations or been close to the estimated EPS.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :-------- | :-------------- |
| 2025-06-30 | $0.31B  | 61.99%        |
| 2025-03-31 | $0.26B  | 60.69%        |
| 2024-12-31 | $0.20B  | 60.83%        |
| 2024-09-30 | $0.18B  | 58.50%        |
| 2024-06-30 | $0.17B  | 45.50%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
| :--------- | :-------- | :--------- |
| 2025-06-30 | $0.31B  | -13.84%  |
| 2025-03-31 | $0.33B  | -20.86%  |
| 2024-12-31 | $0.06B  | -23.10%  |
| 2024-09-30 | $0.05B  | -141.16% |
| 2024-06-30 | $0.10B  | -562.04% |

**Analysis:**

*   **Revenue:** Revenue has been steadily increasing, indicating growth.
*   **Profit Margin:** The profit margin is high and relatively stable, which is a positive sign.
*   **Equity:** Equity has fluctuated but has generally increased.
*   **ROE (Return on Equity):** The ROE is negative, indicating that the company is not generating profits from its equity.

### 7. Overall Assessment

Tempus AI (TEM) presents a mixed investment picture:

*   **Strengths:**
    *   Outperformance of the S&P 500.
    *   High CAGR and positive alpha.
    *   Increasing revenue and high profit margins.
    *   Positive analyst consensus.
    *   Recent positive news catalysts (partnerships, FDA approvals).
*   **Weaknesses/Risks:**
    *   High Maximum Drawdown (MDD) indicating significant price volatility.
    *   Negative EPS and ROE, indicating current lack of profitability.
    *   Recent downgrade due to valuation concerns.
    *   Hybrid signal to sell due to risk.
    *   RSI approaching oversold territory.

**Conclusion:**

TEM exhibits strong growth potential with promising AI-driven technology and increasing revenue. However, the company's lack of profitability, high volatility, and recent downgrade indicate that it carries significant risk. The recent price increase (change of 2.78) may reflect a short-term rebound. Investors should carefully weigh the potential upside against the considerable risks before investing in TEM. Further monitoring of earnings and cash flow is recommended.
